The Efficacy and Safety of Standardized Allergen-Removed Rhus verniciflua Extract as Maintenance Therapy after First-Line Chemotherapy in Patients with …
J Lee, J Chae, S Lee, K Kim, W Eo, S Kim… - The American journal …, 2013 - World Scientific
Chemotherapy improves the survival of patients with advanced non-small cell lung cancer
(NSCLC), but tumor progression is often inevitable. Strategies are needed to improve the …
(NSCLC), but tumor progression is often inevitable. Strategies are needed to improve the …
[HTML][HTML] Long-term survival of advanced lung adenocarcinoma by maintenance chemotherapy followed by EGFR-TKI: A case report
HJ Chen, JM Shen, YN Lin, W Du, JP Zhou, QY Li - Medicine, 2021 - journals.lww.com
Abbreviations: CEA= carcinoembryonic antigen, CT= computed tomography, DDP=
cisplatin, DTX= docetaxel, EGFR= epidermal growth factor receptor, EGFR-TKI= epidermal …
cisplatin, DTX= docetaxel, EGFR= epidermal growth factor receptor, EGFR-TKI= epidermal …
Maintenance therapy in metastatic solid tumors: innovative strategy or Simple second-line treatment?
E Rowinski, P Fournel, E Bernichon… - American Journal of …, 2019 - journals.lww.com
Managing metastatic diseases involves defining the best strategy that is supposed to take
into account both efficacy and quality of life. To this end, clinicians use stop and go or …
into account both efficacy and quality of life. To this end, clinicians use stop and go or …
[图书][B] Developing the agenda for core outcome set development
E Gargon - 2016 - search.proquest.com
Introduction and aims: A core outcome set (COS) is defined as an agreed standardised set
of outcomes that should be measured and reported, as a minimum, in all clinical trials in …
of outcomes that should be measured and reported, as a minimum, in all clinical trials in …
The PARAMOUNT trial: A phase III randomized study of maintenance pemetrexed versus placebo immediately following induction first-line treatment with pemetrexed …
C Gridelli, P Maione, A Rossi - Reviews on Recent Clinical …, 2013 - ingentaconnect.com
The search for new agents and for innovative strategies is warranted in the treatment of
advanced non small cell lung cancer (NSCLC) because the outcomes remain unsatisfactory …
advanced non small cell lung cancer (NSCLC) because the outcomes remain unsatisfactory …
The role of maintenance therapy in the treatment of elderly non-small-cell lung cancer patients: a meta-analysis of randomized controlled trials
L Zhang, S Gao, J He - Drug Design, Development and Therapy, 2017 - Taylor & Francis
Purpose Maintenance therapy is an effective treatment strategy for advanced non-small-cell
lung cancer (NSCLC). We aim to investigate whether age would affect the efficacy of …
lung cancer (NSCLC). We aim to investigate whether age would affect the efficacy of …
Safety and efficacy of Racotumomab-Alum vaccine as second-line therapy for advanced non-small cell lung cancer
E Santiesteban, L Perez, S Alfonso… - … Journal of Clinical …, 2014 - library.thepustakas.com
Despite extensive clinical research in non-small cell lung cancer (NSCLC), overall survival
is still poor. Racotumomab-alum is an anti-idiotypic cancer vaccine that targets NeuGcGM3 …
is still poor. Racotumomab-alum is an anti-idiotypic cancer vaccine that targets NeuGcGM3 …
Maintenance Therapy in Advanced Non-Small Cell Lung Cancer.
D Isla, N Galán - Cancer & Chemotherapy Reviews, 2015 - search.ebscohost.com
Maintenance therapy represents a new treatment paradigm for fit, untreated, advanced non-
small cell lung cancer patients when administering modern chemotherapeutic or targeted …
small cell lung cancer patients when administering modern chemotherapeutic or targeted …
[HTML][HTML] EGFR TKIs as maintenance therapy in NSCLC: finding the old in the new INFORMation
L Landi, F Cappuzzo - Translational Lung Cancer Research, 2012 - ncbi.nlm.nih.gov
PFS (4.6 versus 4.3 months; HR 0.68, 95% CI, 0.57-0.80, P< 0.001), with the greatest benefit
observed in patients with adenocarcinoma histology (5.1 versus 4.4 months; HR 0.60, 95 …
observed in patients with adenocarcinoma histology (5.1 versus 4.4 months; HR 0.60, 95 …